2022. Discontinuation rate of dual antiretroviral therapy with dolutegravir plus lamivudine in people living with HIV: a systematic review. Research, Society and Development. 11, 12 (Sep. 2022), e430111234758. DOI:https://doi.org/10.33448/rsd-v11i12.34758.